These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 38310500)

  • 21. Can Congress Get 'Right to Try' Right?
    Kirkner RM
    Manag Care; 2018 May; 27(5):10-11. PubMed ID: 29763399
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Society for Clinical Trials opposes US legislation to permit marketing of unproven medical therapies for seriously ill patients.
    Society for Clinical Trials Board of Directors
    Clin Trials; 2006; 3(2):154-7. PubMed ID: 16773958
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Baby doe redux? The Department of Health and Human Services and the Born-Alive Infants Protection Act of 2002: a cautionary note on normative neonatal practice.
    Sayeed SA
    Pediatrics; 2005 Oct; 116(4):e576-85. PubMed ID: 16199687
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Right-to-try laws and individual patient "compassionate use" of experimental oncology medications: A call for improved provider-patient communication.
    Hoerger M
    Death Stud; 2016; 40(2):113-20. PubMed ID: 26313583
    [TBL] [Abstract][Full Text] [Related]  

  • 26. From bench to FDA to bedside: US regulatory trends for new stem cell therapies.
    Knoepfler PS
    Adv Drug Deliv Rev; 2015 Mar; 82-83():192-6. PubMed ID: 25489841
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Principled compassion.
    Nat Med; 2014 Dec; 20(12):1355. PubMed ID: 25473904
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The origins of American health libertarianism.
    Grossman LA
    Yale J Health Policy Law Ethics; 2013; 13(1):76-134. PubMed ID: 23815041
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Unproven stem cell-based interventions & physicians' professional obligations; a qualitative study with medical regulatory authorities in Canada.
    Zarzeczny A; Clark M
    BMC Med Ethics; 2014 Oct; 15():75. PubMed ID: 25315976
    [TBL] [Abstract][Full Text] [Related]  

  • 30. State parity laws and access to treatment for substance use disorder in the United States: implications for federal parity legislation.
    Wen H; Cummings JR; Hockenberry JM; Gaydos LM; Druss BG
    JAMA Psychiatry; 2013 Dec; 70(12):1355-62. PubMed ID: 24154931
    [TBL] [Abstract][Full Text] [Related]  

  • 31. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Concise Review: A Comprehensive Analysis of Reported Adverse Events in Patients Receiving Unproven Stem Cell-Based Interventions.
    Bauer G; Elsallab M; Abou-El-Enein M
    Stem Cells Transl Med; 2018 Sep; 7(9):676-685. PubMed ID: 30063299
    [TBL] [Abstract][Full Text] [Related]  

  • 33. State legislation on abortion after Roe v. Wade: selected constitutional issues.
    Bryant MD
    Am J Law Med; 1976; 2(1):101-32. PubMed ID: 973625
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The New Federalism: State Policies Regarding Embryonic Stem Cell Research.
    Acosta ND; Golub SH
    J Law Med Ethics; 2016 Sep; 44(3):419-36. PubMed ID: 27587447
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Unproven stem cell therapies: is it my right to try?
    Riva L; Campanozzi L; Vitali M; Ricci G; Tambone V
    Ann Ist Super Sanita; 2019; 55(2):179-185. PubMed ID: 31264641
    [TBL] [Abstract][Full Text] [Related]  

  • 36. US stem cell clinics, patient safety, and the FDA.
    Turner L
    Trends Mol Med; 2015 May; 21(5):271-3. PubMed ID: 25945404
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The ethical plausibility of the 'Right To Try' laws.
    Carrieri D; Peccatori FA; Boniolo G
    Crit Rev Oncol Hematol; 2018 Feb; 122():64-71. PubMed ID: 29458791
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Do "any willing provider" and "freedom of choice" laws affect HMO market share?
    Morrisey MA; Ohsfeldt RL
    Inquiry; 2003; 40(4):362-74. PubMed ID: 15055835
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.
    Caulfield T; Murdoch B
    BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The laws that affect abortion in the United States and their impact on women's health.
    Harrison LK; Naylor KL
    Nurse Pract; 1991 Dec; 16(12):53-9. PubMed ID: 1798604
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.